Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/98687
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWinter, Annja-
dc.contributor.authorLetang, Emilio-
dc.contributor.authorKalinjuma, Aneth Vedastus-
dc.contributor.authorKimera, Namvua-
dc.contributor.authorNtamatungiro, Alex J.-
dc.contributor.authorGlass, Tracy R.-
dc.contributor.authorMoradpour, Darius-
dc.contributor.authorSahli, Roland-
dc.contributor.authorLe Gal, Frédéric-
dc.contributor.authorFurrer, Hansjakob-
dc.contributor.authorWandeler, Gilles-
dc.contributor.authorKIULARCO Study Group-
dc.date.accessioned2016-05-19T11:05:01Z-
dc.date.available2016-05-19T11:05:01Z-
dc.date.issued2016-05-
dc.identifier.issn1201-9712-
dc.identifier.urihttp://hdl.handle.net/2445/98687-
dc.description.abstractOBJECTIVES: The epidemiological and clinical determinants of hepatitis delta virus (HDV) infection in Sub-Saharan Africa are ill-defined. The prevalence of HDV infection was determined in HIV/hepatitis B virus (HBV) co-infected individuals in rural Tanzania. METHODS: All hepatitis B virus (HBV)-infected adults under active follow-up in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) were screened for anti-HDV antibodies. For positive samples, a second serological test and nucleic acid amplification were performed. Demographic and clinical characteristics at initiation of antiretroviral therapy (ART) were compared between anti-HDV-negative and positive patients. RESULTS: Among 222 HIV/HBV co-infected patients on ART, 219 (98.6%) had a stored serum sample available and were included in the study. Median age was 37 years, 55% were female, 46% had World Health Organization stage III/IV HIV disease, and the median CD4 count was 179 cells/mul. The prevalence of anti-HDV positivity was 5.0% (95% confidence interval 2.8-8.9%). There was no significant predictor of anti-HDV positivity. HDV could not be amplified in any of the anti-HDV-positive patients and the second serological test was negative in all of them. CONCLUSIONS: No confirmed case of HDV infection was found among over 200 HIV/HBV co-infected patients in Tanzania. As false-positive serology results are common, screening results should be confirmed with a second test.-
dc.format.extent3 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier Inc.-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1016/j.ijid.2016.03.011-
dc.relation.ispartofInternational Journal of Infectious Diseases, 2016, vol. 46, p. 8-10-
dc.relation.urihttp://dx.doi.org/10.1016/j.ijid.2016.03.011-
dc.rightscc by-nc-nd (c) Winter et al., 2016-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/-
dc.sourceArticles publicats en revistes (ISGlobal)-
dc.subject.classificationVIH (Virus)-
dc.subject.classificationVirus de l'hepatitis delta-
dc.subject.otherHIV (Viruses)-
dc.subject.otherHepatitis D (hepatitis delta)-
dc.titleAbsence of hepatitis delta infection in a large rural HIV cohort in Tanzania-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2016-05-10T15:02:08Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid26996457-
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
PIIS1201971216309985.pdf266.94 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons